HeXembio key facts
as of Oct 2026- Developer of a cell restoration technology designed to enable longevity.
- HeXembio is valued at approximately $25.0M as of Oct 2026 (last reported valuation).
- It has raised $19.8M.
- Notable investors include Alumni Ventures, SOSV, Gaingels, Draper Associates, IndieBio — 23 tracked in total.
- Status: Privately Held (backing).
HeXembio's last reported valuation, Mar 2025. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch HeXembio: the Monday email on marks, rounds and moves
HeXembio funding rounds
No funding rounds for HeXembio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs HeXembio
23+Membership and data by Private Market View
HeXembio valuation
HeXembio's last reported valuation was $25 million in Mar 2025. No priced round, secondary trade or fund mark has surfaced since.
HeXembio investors
23 investors are on record for HeXembio, including Alumni Ventures, SOSV, Gaingels and Draper Associates. By type, the record holds 8 venture capital firms and 1 growth equity firm.
About HeXembio
Developer of a cell restoration technology designed to enable longevity. The company offers regenerative medicine approaches with scalable and reproducible stem cell therapies, enabling aging individuals to restore healthy hematopoietic stem cell function and reverse the effects of aging.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2024
- Employees
- 8
- Website
- hexemb.io/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.